Kuangli Bio-Tech Holdings Co., Ltd.

Kuangli Bio-Tech Holdings Co., Ltd.

TTWSE:6431
15.80
TWD
-0.05
(-0.32%)
-1.95EPS
1.76BMarket Cap
Kuangli Bio-Tech Holdings Co., Ltd.
TWSE:6431
(Taiwan Stock Exchange)

Recent

price

15.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
28.71
24.91
9.11
4.6
2.33
2.19
9.32
1.91
6.55
6.07
5.13
5.56
4.05
3.74
Revenue per Share
1.87
1.83
-4.54
-5.93
-3.47
-0.41
-0.6
-1.38
0.51
-1.22
-1.82
-2.52
-2.07
-1.99
Basic EPS, GAAP
3.31
4.82
-0.62
-0.15
-1.12
-0.49
-2.07
- -
-0.37
-0.77
-1.53
-1.21
-1.66
-2.61
Free Cash Flow per Basic Share
2.37
2.46
2.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
26.17
27.62
20.1
12.93
9.29
8.71
7.69
6.88
9.42
9.77
7.77
6.35
5.93
5.19
Book Value per Share
26.08
27.56
20.07
12.92
9.28
8.71
7.69
6.87
2.74
4.01
2.56
2.58
3.41
2.68
Tangible Book Value per Share
40
40
46
46
46
46
46
46
51
56
57
69
93
97
Basic Weighted Avg Shares
1,138
1,000
417
211
107
100
425
87
333
342
293
381
377
363
Sales/Revenue/Turnover
20.65
11.6
-61.67
-147.99
-138.69
-44.67
-10.36
-56.89
-3.5
-25.95
-39
-36.21
-39.42
-40.53
Operating Margin (%)
61
68
82
73
51
1
8
8
40
61
61
84
87
86
Depreciation Expense
74
74
-208
-271
-159
-19
-28
-63
26
-69
-104
-173
-193
-193
Net Income, GAAP
36.63
35.9
- -
- -
- -
- -
- -
- -
8.04
- -
- -
- -
- -
- -
Effective Tax Rate (%)
6.51
7.36
-49.85
-128.79
-149.04
-18.86
-6.48
-72.29
7.77
-20.09
-35.51
-45.32
-51.18
-53.13
Profit Margin (%)
669
823
581
472
393
369
238
124
195
127
23
-59
122
40
Working Capital
- -
- -
- -
- -
- -
- -
1
5
176
170
200
140
263
256
LT Debt
1,038
1,264
920
592
425
399
352
314
742
673
558
460
580
511
Total Equity
- -
6.43
- -
- -
- -
- -
- -
- -
-0.96
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
6.4
- -
- -
- -
- -
- -
- -
3.29
- -
- -
- -
- -
- -
Return on Capital (%)
- -
6.4
-19.03
-35.91
-31.24
-4.58
-7.34
-18.89
6.49
-13.19
-20.75
-38.2
-37.21
-34.12
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
225
244
254
LT Borrowings
6
6
5
LT Finance Leases
256
256
250
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
97
97
97
Market Capitalization
2,620
2,289
1,758

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
464
453
403
Cash, Cash Equivalents & STI
310
291
222
Accounts Receivable, Net
82
74
65
Inventories
47
55
60
Total Current Liabilities
342
370
363
Payables & Accruals
- -
- -
- -
ST Debt
225
244
254
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.62%
23.75%
26.17%
Free Cash Flow
19,003.15%
37,860.52%
86.84%
Net Income, GAAP
-30.27%
-75.59%
11.68%
Sales/Revenue/Turnover
44.03%
59.98%
-1.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62
89
105
124
381
2025
110
86
67
114
377
2026
86
96
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.62
-0.62
-0.43
-0.85
-2.52
2025
-0.46
-0.55
-0.43
-0.63
-2.07
2026
-0.4
-0.53
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Kuangli Bio-Tech Holdings Co., Ltd. engages in the production, design, and sale of optical panels and lenses primarily for consumer electronics. Its main products include smartphone and tablet cover glass; mobile phone and tablet camera lenses; acrylic material plexiglass and other flat panels; tempered glass; I.com touch panels; decorative parts and buttons for electronic devices; as well as optical panels for HD players, digital cameras, home appliances, MP3/MP4 players, car logs, lampshades, and medical equipment. The company serves the consumer electronics industry with a focus on protective glass and decorative components used in mobile phones, tablets, laptops, and various digital devices. Founded in 2002, Kuangli Bio-Tech is headquartered in Kunshan, China, and operates with distribution in domestic and international markets including Mainland China, Taiwan, and Korea. In recent years, Kuangli Bio-Tech expanded into medical biotechnology through its subsidiary Taiwan Kuangli Co., Ltd., which launched the G CLINIC International Medical System in 2022. This healthcare initiative integrates advanced technology and franchising to provide premium, self-funded health management services focusing on neuro, circulatory, and metabolic medicine. Strategically, the company enhanced its portfolio by acquiring a 75% stake in Shanghai Thinkstart Automation Technology Co., Ltd. and signing an agreement to acquire 70% of Shanghai Hengjun, thereby strengthening its automation and technological capabilities. Additionally, Kuangli Bio-Tech has made organizational changes including Compensation Committee and Board changes during 2025 to support its evolving business model. Kuangli Bio-Tech Holdings maintains its position in the household and personal product sector under the consumer staples industry. The company’s business segments include electronic equipment components and medical biotechnology health services, operating primarily across Taiwan, Mainland China, Korea, and other Asian markets. Its comprehensive product range and recent strategic expansions into healthcare and automation underline its efforts to diversify beyond traditional electronic component manufacturing. The stock is listed on the Taiwan Stock Exchange under ticker 6431.TW. The company continues to invest in technology and healthcare integration, reflecting a strategic shift towards smart healthcare solutions alongside its established electronic hardware business.